|
Today's Headlines
FDA has approved radium Ra 223 dichloride (Xofigo, Bayer) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.
» Full article
|
|
FDA has approved fluticasone furoate and vilanterol inhalation powder (Breo Ellipta, GlaxoSmithKline and Theravance), an inhaled long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.
» Full article
|
|
Because of the need for early detection, improved antiviral agents, and changes in the availability of commercial hepatitis C virus tests, the Centers for Disease Control and Prevention has issued a new guidance for clinicians and laboratorians. » Full article
|
Continuing Education
Welcome to our CPE series: Pain Management Considerations for Medication Therapy Management, which has been designed for pharmacists who take care of patients who need pain relief. You can earn up to 10 credits from April 2013 to August 2013 with 5 monthly knowledge-based activities and 2 credits from September 2013 to October 2013 with 2 monthly interactive online case studies.
The May activity covers pharmacology and therapeutics of pain medications, focusing on non-opioid analgesics.
To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in.
Announcement: Welcome to the new user registration process. This new process requires all pharmacists and pharmacy technicians to provide
or update their NABP e-Profile ID in order to electronically keep track of CPE credits from ACPE-accredited providers. If you have not done so, you can obtain your NABP e-Profile ID now at
www.MyCPEmonitor.net. This profile will enable you to have one login
for all the NABP programs and services you will need throughout your career.
|
|
EDITOR'S PICK
Medication Reconciliation, “med rec” as it has come to be known, is recognized as an important part of the growing practice of medication management and a critical step in improving the care of patients in all settings. Despite the many challenges associated with implementation of a successful med rec program, the potential for significant value drives the ongoing effort to find scalable, cost-effective solutions. » Full article
|
|
|
SURVEY
— Continue to remain the gold standard for
treatment-naïve patients
— Shared first-line role with newer
non-interferon regimens
— Reserved primarily for 2nd-line use in
patients failing interferon-free regimen
— Very minimal role moving forward
Click Here to let us know.
|
|
Like
Tweet
